Cantor Fitzgerald LP’s lawsuit alleging a firm founded by four of its former investment bankers stole clients worth millions of dollars in profit was dismissed by a New York judge.

Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), which currently trades at $438.40 with a market capitalization of $112.

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that

Cantor Fitzgerald analyst Sarah James maintained a Buy rating on Cigna (CI – Research Report) yesterday and set a price target of $350.00. The

“As you can imagine, the pain we suffered with Gary and 657 of my other friends and colleagues at Cantor Fitzgerald were killed on 9/11,” Lutnick said during his confirmation hearing before ...

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald currently has a “Overweight” rating and a $44.00 price objective on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.33) per share.

Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested

Donald Trump's commerce secretary nominee told his US Senate confirmation hearing Wednesday he favors "across-the-board" tariffs targeting countries rather than products, while signaling a hawkish China stance.

Fintel reports that on January 30, 2025, Cantor Fitzgerald upgraded their outlook for Lam Research (NasdaqGS:LRCX) from Neutral to Overweight. Analyst Price Forecast Suggests 13.99% Upside As of January 28,

Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in the field of precision medicine,

Cantor Fitzgerald analyst Jonathan Ruykhaver tells investors that the firm’s checks on Check Point (CHKP) remain consistent and “encouraging,” suggesting improved near-term performance.